Weight Loss Medications, Drugs & Pills (2026)

Every FDA-approved weight loss medication, drug, and pill in 2026 — GLP-1 receptor agonists for chronic weight management (Wegovy, Zepbound, Foundayo, Saxenda), the type-2-diabetes GLP-1s commonly prescribed off-label (Ozempic, Mounjaro), non-GLP-1 anti-obesity pills (Qsymia, Contrave, Xenical), and the pipeline drugs in late-phase trials. Verified primary-source data, brand by brand.

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

Always verify pricing and state availability on the provider's website before signing up.How our reviews work →

About this page

Every drug below is FDA-approved with a published label on DailyMed (NIH) or Drugs@FDA. The mechanism, indication, administration route, and approval-date data are pulled from our primary-source-verified drug database — see each drug's linked guide for verbatim FDA-label quotes, clinical-trial citations, and the editorial verification log. We do not paraphrase indication language and we do not invent comparisons that the published evidence does not support.

Weight loss pills vs weight loss injections

Weight loss medications come in two administration formats: oral pills (taken by mouth) and subcutaneous injections (self-administered, typically once weekly). The choice between them depends on FDA-approved indication, tolerability of needles, dosing convenience, and insurance coverage.

Weight loss pills (oral)

FDA-approved oral weight-loss options as of 2026:

  • Foundayo (orforglipron) — GLP-1 RA, daily tablet, FDA-approved April 2026
  • Rybelsus (oral semaglutide) — GLP-1 RA for type 2 diabetes (off-label for weight loss), daily tablet
  • Qsymia (phentermine + topiramate) — non-GLP-1, daily capsule, FDA-approved 2012
  • Contrave (naltrexone + bupropion) — non-GLP-1, twice-daily tablet, FDA-approved 2014
  • Xenical / alli (orlistat) — non-GLP-1, three times daily, FDA-approved 1999 (Rx) / 2007 (OTC alli)

Weight loss injections (subcutaneous)

FDA-approved injectable weight-loss options:

  • Wegovy (semaglutide 2.4 mg) — once weekly, FDA-approved June 2021
  • Zepbound (tirzepatide) — once weekly, FDA-approved November 2023
  • Saxenda (liraglutide 3 mg) — once daily, FDA-approved December 2014
  • Ozempic (semaglutide for T2D) — once weekly, off-label for weight loss
  • Mounjaro (tirzepatide for T2D) — once weekly, off-label for weight loss

For a deep dive on the GLP-1 receptor agonist drug class specifically — what it is, how it works, every FDA-approved GLP-1, and how brand-name overlaps work — see our GLP-1 complete guide.

GLP-1 receptor agonists indicated for chronic weight management

These are the drugs FDA-approved specifically for weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbid condition.

Wegovy

Semaglutide
Drug class
GLP-1 receptor agonist
Administration
Subcutaneous injection (single-dose pre-filled pen)
Manufacturer
Novo Nordisk A/S
FDA indication
Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity; cardiovascular risk reduction in adults with obesity and established cardiovascular disease

FDA status: FDA-approved for chronic weight management in adults with obesity or overweight with comorbidity (June 2021); FDA-approved for cardiovascular risk reduction in adults with established CVD (March 2024)

Full Wegovy guide →

Zepbound

Tirzepatide
Drug class
GIP and GLP-1 receptor agonist (dual incretin)
Administration
Subcutaneous injection (single-dose pre-filled pen and vial)
Manufacturer
Eli Lilly and Company
FDA indication
Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity; obstructive sleep apnea in adults with obesity

FDA status: FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity (November 2023)

Full Zepbound guide →

Foundayo

Orforglipron
Drug class
GLP-1 receptor agonist (oral non-peptide small molecule)
Administration
Oral, once daily
Manufacturer
Eli Lilly and Company
FDA indication
Chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity

FDA status: FDA-approved for chronic weight management in adults with obesity, or overweight with weight-related medical problems, alongside a reduced-calorie diet and increased physical activity (April 1, 2026). Not approved for pediatric use. Cannot be used with other GLP-1 receptor agonists.

Full Foundayo guide →

GLP-1s indicated for type 2 diabetes — commonly used off-label for weight loss

These drugs are FDA-approved for glycemic control in type 2 diabetes, not for weight loss alone. They are commonly prescribed off-label for weight loss when weight-management-indicated drugs are unavailable or not covered. Off-label prescribing is legal and common, but often not covered by insurance for this use.

Ozempic

Semaglutide
Drug class
GLP-1 receptor agonist
Administration
Subcutaneous injection (multi-dose pre-filled pen)
Manufacturer
Novo Nordisk A/S
FDA indication
Glycemic control in type 2 diabetes mellitus; cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease

FDA status: FDA-approved for glycemic control in type 2 diabetes (December 2017); FDA-approved to reduce cardiovascular risk in adults with T2DM and established CVD (2020). Weight loss is off-label use.

Full Ozempic guide →

Mounjaro

Tirzepatide
Drug class
GIP and GLP-1 receptor agonist (dual incretin)
Administration
Subcutaneous injection (single-dose pre-filled pen)
Manufacturer
Eli Lilly and Company
FDA indication
Glycemic control in adults with type 2 diabetes mellitus

FDA status: FDA-approved for type 2 diabetes (May 2022). Off-label use for weight loss is common; the weight management indication is covered by Zepbound (FDA-approved November 2023).

Full Mounjaro guide →

Pipeline: drugs in late-stage clinical trials

These investigational drugs have published phase 2 or phase 3 trial data but are not yet FDA-approved. For trial-by-trial NCT IDs, primary completion dates, and verified topline results, see our comprehensive GLP-1 Pipeline Tracker (2026). Quick summary below:

  • Retatrutide — Eli Lilly. Triple agonist (GLP-1 / GIP / glucagon). The strongest weight-loss readout in any GLP-1 trial to date. See our retatrutide evidence article.
  • CagriSema — Novo Nordisk. Cagrilintide (amylin analog) + semaglutide combination. See the CagriSema REDEFINE results.
  • MariTide (maridebart cafraglutide) — Amgen. GLP-1 / GIP receptor modulator with monthly dosing. See the GLP-1 pipeline article.
  • Survodutide — Boehringer Ingelheim & Zealand Pharma. GLP-1 / glucagon dual agonist. Coverage in the same pipeline article.
  • Ecnoglutide — Sciwind. Long-acting GLP-1 RA in late-stage trials. Coverage in the pipeline article.

Other FDA-approved anti-obesity medications

The FDA has approved additional non-GLP-1 medications for chronic weight management — including Saxenda (liraglutide), Qsymia (phentermine + topiramate), Contrave (naltrexone + bupropion), Xenical / alli (orlistat), Plenity (cellulose hydrogel device), and Imcivree (setmelanotide for rare genetic obesity). We link to canonical FDA sources below while our verification queue advances.

Authoritative FDA-published landscape: NIDDK — Prescription Medications to Treat Overweight & Obesity. Drugs@FDA database for current label of any specific drug. We'll add dedicated guides for each of the older AOMs as our verification queue advances.

Common questions

The questions patients and caregivers most frequently ask about FDA-approved weight-loss medications.

Which GLP-1 medications are FDA-approved specifically for weight loss in 2026?
Three GLP-1 receptor agonists are FDA-approved for chronic weight management as of 2026: Wegovy (semaglutide subcutaneous, Novo Nordisk, June 2021), Zepbound (tirzepatide subcutaneous, Eli Lilly, November 2023), and Foundayo (orforglipron oral, Eli Lilly, April 1 2026). Saxenda (liraglutide, Novo Nordisk, December 2014) is also FDA-approved but is now infrequently prescribed since the more-effective semaglutide and tirzepatide products launched.
Are Ozempic and Mounjaro FDA-approved for weight loss?
No. Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved only for type 2 diabetes glycemic control. Their identical active ingredients are sold under different brand names — Wegovy and Zepbound — for the weight-management indication. Off-label prescribing of Ozempic or Mounjaro for weight loss is legal but is typically not covered by insurance for that use.
What is the difference between Wegovy and Zepbound?
Wegovy is semaglutide (a GLP-1 receptor agonist). Zepbound is tirzepatide (a dual GIP and GLP-1 receptor agonist). In SURMOUNT-1 (Jastreboff et al., NEJM 2022), tirzepatide 15 mg produced ~21% mean body-weight loss at 72 weeks, vs ~15% for semaglutide 2.4 mg in STEP-1 (Wilding et al., NEJM 2021). Both are subcutaneous injections taken once weekly. Their FDA-approved weight-management indications are nearly identical (BMI ≥30 or ≥27 with weight-related comorbidity).
What is Foundayo and how is it different from injectable GLP-1s?
Foundayo (orforglipron) is the first oral, non-peptide GLP-1 receptor agonist FDA-approved for chronic weight management (Eli Lilly, April 1 2026). Unlike Rybelsus (oral semaglutide), it is a small-molecule drug, not a modified peptide — meaning it does not require special fasting protocols at administration. It is taken once daily as a tablet. Foundayo is FDA-approved for adults only and cannot be used concurrently with other GLP-1 receptor agonists.
When will retatrutide and other pipeline GLP-1s be approved?
As of 2026-05-09, retatrutide (Eli Lilly triple agonist), MariTide / maridebart cafraglutide (Amgen), CagriSema (Novo Nordisk), survodutide (Boehringer Ingelheim & Zealand Pharma), and ecnoglutide (Sciwind) are all in late-stage clinical trials but NOT yet FDA-approved. Trial readouts (TRIUMPH, ATTAIN, REDEFINE, MariTide phase 3) determine the timeline. Retatrutide has produced the strongest weight-loss signals to date in any GLP-1 trial. See our linked evidence articles in the Pipeline section above for the latest published trial data.
Are there FDA-approved weight-loss medications that are not GLP-1s?
Yes. FDA-approved non-GLP-1 anti-obesity medications include Qsymia (phentermine + topiramate), Contrave (naltrexone + bupropion), Xenical / alli (orlistat), Plenity (cellulose hydrogel), and Imcivree (setmelanotide for rare genetic obesity). These predate the GLP-1 era and are typically less effective for weight loss but remain prescribed for patients who cannot tolerate or access GLP-1s. For canonical FDA information on every approved AOM, see the NIDDK landscape overview linked in the section above.

Where to go next

Best semaglutide providers →
Compounded and brand-name semaglutide telehealth providers, ranked by price + transparency.
Best tirzepatide providers →
Compounded and brand-name tirzepatide telehealth providers, ranked by price + transparency.
Live GLP-1 pricing index →
Brand list prices vs compounded cash-pay vs savings-card paths across every channel we track.
Insurance coverage by insurer →
Cigna, Aetna, UnitedHealthcare, Humana, Anthem BCBS, Kaiser, Medicare, Medicaid — verified PA criteria and copay data.
Research library →
YMYL evidence-based articles on side effects, drug interactions, long-term outcomes, peri-operative guidance, and bariatric vs GLP-1 decision support — all primary-source verified.